Gemcovac-19, mRNA vaccine, has Emergency use Authorisation in India against COVID 19.
Gemcovac-19, mRNA vaccine, has Emergency use Authorisation in India against COVID 19
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, announced that its mRNA vaccine - Gemcovac-19 - against Covid-19 received the Emergency Use Authorization (EUA) from the office of the Drugs Controller General of India (DCGI). Gemcovac-19 is the very first mRNA vaccine developed in India and only third mRNA vaccine to be approved for COVID-19 in the world.
Gennova Biopharmaceuticals Ltd aims to produce around 4 - 5 million doses per month and this capacity can be quickly doubled. Apart from India, Gennova aims to provide access to low-and middle-income countries around the world to the vaccine to blunt the spread of pandemic.
As mRNA vaccines are required to be kept at sub-zero temperatures, it was a mammoth task for Gennova scientists to develop a thermostable mRNA Covid-19 vaccine. Scientists had to innovate to suit local needs to make it affordable and deployable. The new vaccine can now be stored at the temperature of a standard medical refrigerator.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.